The Chronically Colonized Neurogenic Bladder: When Does “Don’t Treat” Stop Applying
Every patient on intermittent catheterization is colonized, and the guideline is clear that colonization alone isn't treated. The disagreement is whether this particular set of symptoms is still just colonization.
Grace L., a 58-year-old woman who sells watercolor paintings of the coastline at a Saturday market she has not missed in six years, sustained a T5 complete spinal cord injury in a car accident two decades ago and has performed clean intermittent catheterization ever since, a routine she describes as more automatic to her at this point than checking her phone. A urine culture drawn as part of a routine annual visit grew over 100,000 colony-forming units of E. coli — an entirely ordinary finding in a CIC-dependent patient, present in essentially all such patients at some point and, by the current guideline, not a reason to treat on its own. What brought her back three days later wasn't a fever or burning, the symptoms that would ordinarily separate infection from mere colonization, but three days of noticeably worse spasticity and two episodes of unexplained sweating, both of which she initially attributed to the heat.
Her neurological level, T5, sits above the threshold at which classic infection symptoms — dysuria, suprapubic pain — may simply not register the way they would in a patient with intact sensation below the injury, and autonomic dysreflexia is a documented, if underrecognized, presentation of urinary infection in exactly this population, standing in for the pain she cannot otherwise feel. Her pressure in clinic today reached 168/98 before settling on its own — a reading nobody would look at twice in most fifty-eight-year-olds, but well above her own recorded baseline, and in a T5 patient with no prior dysreflexia on record it is a third finding in a set rather than an isolated number. The IDSA's 2019 guideline is unambiguous that asymptomatic bacteriuria in spinal cord injury should not be screened for or treated, a recommendation grounded in real trial data showing no difference in symptomatic infection rates between treated and untreated bacteriuria in catheter-dependent patients. But that recommendation was built around patients who are, in fact, asymptomatic — and the entire question in front of the team today is whether new spasticity and sweating in a T5-level patient are a genuine symptom the guideline's own framework didn't anticipate, or an unrelated finding being retrofitted onto a positive culture because the culture happened to be there.
Urgent visit, three days of unusual spasticity
The IDSA guideline is clear, and I don't think we should treat her culture on its own — asymptomatic bacteriuria is essentially universal in CIC-dependent patients, and treating it reflexively has real costs, resistance chief among them. That said, spasticity and sweating aren't nothing in a T5-level patient; her level of injury is exactly the kind where classic infection pain doesn't register, and autonomic dysreflexia can stand in for symptoms she can't otherwise feel.
I agree the guideline doesn't automatically resolve this, but I want to name the risk on the other side plainly, not just concede the point and move on.
A transient blood pressure elevation that's already resolved, and symptoms that could just as easily reflect a bad week, dehydration, or nothing in particular, is a thin basis for overriding a guideline built on real trial data showing treating asymptomatic bacteriuria doesn't reduce symptomatic infection rates in this population. If we treat every ambiguous symptom cluster as evidence enough, we've effectively abandoned the guideline for anyone we can construct a story for.
I don't think this needs to be an all-or-nothing call between the guideline and Grace's own new symptoms. I'd treat the culture today given the specific combination — new spasticity, sweating, and a transient blood pressure spike together, in a patient with no prior history of autonomic dysreflexia — while being explicit that a single ambiguous symptom alone wouldn't have met that bar.
That keeps the guideline intact for the far more common case of colonization with no real change in her baseline, without ignoring a cluster of findings that, taken together, look like a real presentation the guideline's authors would recognize as symptomatic if they were sitting in this room.
Agreed: treat this episode with a culture-directed antibiotic course, given the combination of new spasticity, unexplained sweating, and a transient blood pressure elevation in a patient with no prior autonomic dysreflexia history — explicitly not a decision to treat future isolated positive cultures without new symptoms.
Not fully agreed: the stewardship pharmacist remains uneasy that this decision, however narrowly reasoned today, sets a precedent that could erode adherence to the guideline on a future, less clear-cut presentation; the group agreed to document the specific symptom combination that justified treatment this time, precisely so a future ambiguous case isn't decided by analogy to today without meeting the same bar.